文献速递肾小球疾病

联合血清学与遗传风险评分预测PLA2R相关膜性肾病进展

Combined Serologic and Genetic Risk Score and Prognostication of Phospholipase A2 receptor-Associated Membranous Nephropathy.
PubMed 文献 · Clin J Am Soc Nephrol · 2024-02-29

该回顾性研究纳入519例经活检证实的PLA2R相关原发性膜性肾病患者(基线eGFR≥25 ml/min/1.73 m²),旨在验证联合遗传风险评分与PLA2R抗体滴度的复合风险评分能否改善肾衰竭预测。中位随访67个月,66例(13%)发生肾脏病进展。复合风险评分在临床模型基础上显著提升预测效能(C-statistic 0.82 vs 0.76)。

要点

  • 复合风险评分联合遗传风险评分与PLA2R抗体,优于单用血清学或临床因素预测肾脏病进展。
  • 临床模型(年龄、eGFR、蛋白尿、白蛋白、糖尿病、小管间质病变)C-statistic为0.76。
  • 加入PLA2R抗体后C-statistic升至0.78,替换为复合风险评分进一步升至0.82。

核心结论

  • 在PLA2R相关膜性肾病患者中,联合遗传风险等位基因与PLA2R抗体的复合风险评分较单用PLA2R血清学或临床因素更能预测肾脏病进展。

研究设计与样本

  • 回顾性分析519例经活检证实的PLA2R相关原发性膜性肾病患者,基线eGFR≥25 ml/min/1.73 m²。
  • 复合风险评分由遗传风险评分与PLA2R ELISA抗体滴度组合计算。
  • 主要终点为肾脏病进展,定义为eGFR下降50%或肾衰竭。

主要发现

  • 中位年龄56岁(范围15-82岁),男女比1:0.6,活检时中位eGFR 99 ml/min/1.73 m²(范围26-167),中位蛋白尿5.3 g/24小时(范围1.5-25.8)。
  • 中位随访67个月(范围5-200个月),66例(13%)发生肾脏病进展。
  • PLA2R抗体滴度、遗传风险评分和复合风险评分均独立与肾脏病进展相关(校正年龄、性别、蛋白尿、eGFR和小管间质病变前后均显著)。

临床怎么用

  • 对于PLA2R相关膜性肾病患者,可考虑采用联合遗传风险评分与PLA2R抗体滴度的复合风险评分来增强肾脏病进展的风险分层。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: The aim of this study was to test whether a combined risk score on the basis of genetic risk and serology can improve the prediction of kidney failure in phospholipase A2 receptor (PLA2R)-associated primary membranous nephropathy. METHODS: We performed a retrospective analysis of 519 biopsy-proven PLA2R-associated primary membranous nephropathy patients with baseline eGFR ≥25 ml/min per 1.73 m 2 . The combined risk score was calculated by combining the genetic risk score with PLA2R ELISA antibody titers. The primary end point was kidney disease progression defined as a 50% reduction in eGFR or kidney failure. Cox proportional hazard regression analysis and C-statistics were applied to compare the performance of PLA2R antibody, genetic risk score, and combined risk score, as compared with clinical factors alone, in predicting primary outcomes. RESULTS: The median age was 56 years (range, 15-82 years); the male-to-female ratio was 1:0.6, the median eGFR at biopsy was 99 ml/min per 1.73 m 2 (range: 26-167 ml/min per 1.73 m 2 ), and the median proteinuria was 5.3 g/24 hours (range: 1.5-25.8 g/24 hours). During a median follow-up of 67 (5-200) months, 66 (13%) had kidney disease progression. In Cox proportional hazard regression models, PLA2R antibody titers, genetic risk score, and combined risk score were all individually associated with kidney disease progression with and without adjustments for age, sex, proteinuria, eGFR, and tubulointerstitial lesions. The best-performing clinical model to predict kidney disease progression included age, eGFR, proteinuria, serum albumin, diabetes, and tubulointerstitial lesions (C-statistic 0.76 [0.69-0.82], adjusted R 2 0.51). Although the addition of PLA2R antibody titer improved the performance of this model (C-statistic: 0.78 [0.72-0.84], adjusted R 2 0.61), replacing PLA2R antibody with the combined risk score improved the model further (C-statistic: 0.82 [0.77-0.87], adjusted R 2 0.69, difference of C-statistics with clinical model=0.06 [0.03-0.10], P < 0.001; difference of C-statistics with clinical-serologic model=0.04 [0.01-0.06], P < 0.001). CONCLUSIONS: In patients with PLA2R-associated membranous nephropathy, the combined risk score incorporating inherited risk alleles and PLA2R antibody enhanced the prediction of kidney disease progression compared with PLA2R serology and clinical factors alone.

来源:Clin J Am Soc Nephrol,查看原文。版权归原作者所有。

引用

  1. Hu X, Xu J, Wang W, et al. Combined Serologic and Genetic Risk Score and Prognostication of Phospholipase A2 receptor-Associated Membranous Nephropathy. Clin J Am Soc Nephrol. 2024. PMID: 38423528. doi:10.2215/CJN.0000000000000422

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。